Silo Pharma shares surge 13.72% premarket after partnering with Allucent for FDA IND application of SPC-15 PTSD treatment.

Silo Pharma (NASDAQ: SILO) surged 13.72% in premarket trading following the announcement of a partnership with Allucent to advance its investigational new drug (IND) application for SPC-15, an intranasal PTSD treatment. The company plans to submit the IND to the FDA in 2026, with first-in-human trials contingent on approval. The partnership, leveraging Allucent’s expertise in regulatory and clinical development, is positioned to streamline SPC-15’s progression via the FDA’s 505(b)(2) accelerated pathway. Anticipated GLP-compliant toxicology and drug-device study data in early 2026 further underscore the program’s potential. The news reinforces Silo’s focus on addressing underserved psychiatric disorders and aligns with its broader strategy of advancing novel therapeutics through strategic collaborations.